trending Market Intelligence /marketintelligence/en/news-insights/trending/9zapxzbcvfsjd0xnfwfwqa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche reports deaths of 5 patients using Hemlibra

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche reports deaths of 5 patients using Hemlibra

The Hemophilia Federation of America, or HFA, and the National Hemophilia Foundation said Roche Holding AG unit Genentech Inc. informed them of five deaths of patients using its hemophilia A drug Hemlibra.

Although Genentech did not provide much information, the company noted that the patients had received Hemlibra, also known as emicizumab or ACE910, as part of compassionate use and expanded patient access, HFA said.

HFA, an advocacy organization for rare bleeding disorders, on Feb. 22 disclosed a patient death from the phase 3 Haven 1 study of Hemlibra. "Because the other 4 deaths have been under expanded patient access, or compassionate use, there has been little communication available from Genentech," the HFA said in a statement.

In an email to S&P Global Market Intelligence, Roche confirmed the five patient deaths but noted they were unrelated to the treatment. The company said if any adverse event impacts the overall benefit/risk profile of the medicine, it will share that information as quickly as possible.

SNL Image